Medical Oncology

Genitourinary Cancers

Questions discussed in this category

How do you treat muscle-invasive and metastatic sarcomatoid bladder cancer?

Is there a role for neoadjuvant cisplatin-based chemotherapy? Do patients with sarcomatoid histology respond to checkpoint inhibitors?

1 Answer available

What is the optimal management of recurrent seminoma with small volume retroperitoneal disease initially managed with surveillance?

How does your approach differ for patients with stage IIA versus IIB disease? Age?

3 Answers available

For muscle invasive bladder cancer, after neoadjuvant chemotherapy with cis/gem and surgery with residual tumor and lymph node involvement, would you consider adjuvant avelumab as an extrapolation base on the JAVELIN 100 results?

https://meetinglibrary.asco.org/record/186872/abstract How do you weigh the negative results from IMvigor 010 of adjuvant atezolizumab vs the results...

2 Answers available

How do you stage patients with testicular cancer who may have CSIS disease?

An ASCO 2020 poster from the German Testicular Cancer Study Group found that 37% of CSIS seminoma and nonseminoma were miscatagorized resulting in ina...

1 Answer available

Would you offer neoadjuvant chemotherapy to a patient with muscle-invasive enteric adenocarcinoma of the bladder?

If offering neoadjuvant chemotherapy, which regimen would you use?

1 Answer available

Would you treat a patient with Radium 223 for prostate cancer with mainly bone metastasis if he has a history of osteonecrosis of the jaw bone from bisphosphonate/Denosumab?

1 Answer available

What is your approach to unresectable metastatic rhabdomyosarcoma transformed from an embryonal cell germ cell tumor?

Should treatment be based on current histology (rhabdomyosarcoma) or origin (germ cell)?

1 Answer available

Would you offer systemic therapy after rendered NED from SRS to isolated CNS metastases in a patient with prior curative intent treatment of lung adenocarcinoma and clear cell RCC?

1 Answer available

Would you offer immunotherapy for a patient with a history of kidney transplant on immunosuppression who has clear cell RCC in the native kidney?

Patient has MSKCC high risk disease. Immunosuppression is with mycophenolate mofetil and tacrolimus.

1 Answer available

How do you treat a patient with a history of clinical stage IIb cN2, mixed germ cell embryonal carcinoma treated with BEP and RPLND five years ago, who now has signet ring cell adenocarcinoma with abdominal carcinomatosis with an unknown primary?

GI work up negative. NGS cancer type and isochromosome 12p ordered and pending. Pathology at RPLND was negative for cancer.

3 Answers available

In what situations do you utilize G-CSF in germ cell tumors or Hodgkin lymphoma patients receiving bleomycin?

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

2 Answers available

Is there a role for high-dose chemotherapy in a patient with metastatic choriocarcinoma with brain-only recurrence within two years of diagnosis after prior treatment with first and second line chemotherapy (BEP x4 and VIP x3)?

Brain metastases have undergone resection, SBRT and WBRT

1 Answer available

What is your preferred chemotherapy regimen to give concurrently with radiation for squamous cell differentiation localized bladder cancer?

1 Answer available

Is there any role for neoadjuvant therapy in urothelial Tis refractory to BCG therapy?

1 Answer available

What is the longest acceptable interval between radical orchiectomy and adjuvant BEP for Stage IIB/III pure seminoma in the age of COVID-19?

2 Answers available

Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?

1 Answer available

What scenarios, if any, are you delaying adjuvant chemotherapy in light of the COVID-19 outbreak?

2 Answers available

Have your treatment recommendations for urothelial cancer patients changed given the ongoing COVID19 pandemic?

Would you forego neoadjuvant chemotherapy? Are you using growth factor support differently? Any changes to immunotherapy? Other considerations?

2 Answers available

Would you give abiraterone in the post-prostatectomy setting to patients with positive nodes detected at surgery?

Is there data and FDA approval for this indication? What about for nodal failure after radiation?

1 Answer available

How do you manage TKI induced secondary polycythemia in a patient with RCC?

Is this also a marker of TKI sensitivity?

1 Answer available

Would you offer salvage chemotherapy to a patient with stage IIIC poor risk NSGCT in whom AFP fail to normalize even after 2 months of completion of 4 cycles BEP?

Residual disease with bulky retroperitoneal masses also present on scans

1 Answer available

How do you treat metastatic squamous cell carcinoma of the bladder?

1 Answer available

How do you think about management options in a patient with a minute focus of Gleason grade 4 (4+4) on 1 core from needle biopsy along with only Gleason 3+3 disease in other biopsy cores and PSA<10?

Assuming patient is not a surgical candidate and wishes to pursue definitive radiotherapy, what duration of ADT would you give?

1 Answer available

Do you modify your neoadjuvant considerations for patients with micropapillary histology and pT2 urothelial carcinoma and no distant neoplastic disease?

1 Answer available

Do you recommend routine dental evaluation for all patients before starting bisphosponates in patients with bone metastases?

1 Answer available

How would you treat a patient with metastatic small cell of the prostate who is progressing on cisplatin/etoposide and has previous NGS without actionable mutations?

2 Answers available

Is orchiectomy necessary for a patient with primary retroperitoneal seminoma and calcifications seen on testicular ultrasound (but no primary testicular mass)?

2 Answers available

Would you offer neoadjuvant chemotherapy for a patient with low-grade upper tract/renal pelvis urothelial carcinoma with concurrent bladder drop-metastasis?

1 Answer available

How do you treat metastatic RCC with fumarate hydratase mutation (Hereditary Leiomyomatosis and RCC [HLRCC])?

There was an abstract in European J of Cancer (Srinivasan R, 2014:50: S6, P8) showing a good response rate with Bevacizumab and Erlotinib. Would you u...

1 Answer available

Would you treat unfavorable intermediate risk prostate cancer in the setting of recently resected NSCLC?

How would a much higher risk cancer affect decision making? How would you treat him?

3 Answers available

Is there a role of definitive radiation or prostatectomy, in a patient who has M0 castrate resistant prostate cancer and whose PSA is undetectable on ADT and enzulatamide?

2 Answers available

What is your approach to imaging for localization of biochemical relapse of prostate cancer after radical prostatectomy?

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging. Are you utilizing these speciali...

1 Answer available

Would you treat a patient with testicular cancer stage I, pure seminoma on orchiectomy, but with high bHCG (in 1000s) as seminoma or as non-seminoma?

1 Answer available

What would be the best treatment approach for bladder cancer patients s/p neoadjuvant therapy and surgical resection who develop oligometastatic recurrence within 1 year that is amenable to resection?

2 Answers available

How do you treat metastatic testicular cancer with the primary orchiectomy pathology showing non-seminoma with components of teratoma and primitive neuroectodermal tumor?

Are there any special considerations with the PNET?

1 Answer available

Is it reasonable to offer 3-days BEP regimen to a patient with high risk mixed germ cell tumor due to compliance issues?

3 Answers available

How do you treat elderly or frail patients with metastatic RCC?

1 Answer available

In a patient with M0CRPC with PSA doubling time < 6 months, will you wait until the absolute PSA value is >2, or is PSADT alone sufficient to start an AR targeted agent?

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

3 Answers available

What is the protocol for stopping TKI used in RCC prior to a surgery?

Does the extent of the surgery matter?

1 Answer available

In a patient with primary mediastinal seminoma with normalization of biomarkers s/p EPx4 and residual non-FDG avid mass, would you consider resection of residual tumor vs surveillance?

2 Answers available

What is the best management for a patient with advanced renal medullary carcinoma?

2 Answers available

Do you consider adjuvant chemotherapy in a patient who has received ddMVAC preoperatively and had pT3pN2 disease at time of surgery?

1 Answer available

Would you offer SBRT to a biopsy proven T1 renal cell carcinoma on a transplanted kidney?

1 Answer available

In a patient with pN1 penile squamous cell carcinoma s/p inguinal lymph node dissection, would you offer adjuvant TIP vs adjuvant chemoRT vs surveillance?

1 Answer available

What is the optimal duration of ADT for cN1 disease with EBRT?

3 Answers available

Would you offer PA nodal XRT in a patient with rising PSA and multiple PET positive nodes after previous prostate XRT treatment that is otherwise locally controlled?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

2 Answers available

When would you consider active surveillance for a patient with metastatic RCC?

NCCN include active surveillance as an option in specific circumstances based on Rini et al. (Lancet Oncology 2016) however this set is not well defin...

1 Answer available

How would you treat a patient who has progression of nodal metastases while receiving neoadjuvant gemcitabine/cisplatin?

Any role to switch to MVAC?

1 Answer available

How would you treat a patient with newly diagnosed advanced urothelial cancer?

Would you treat with chemoimmunotherapy based on IMvigor130 data presented at ESMO Congress 2019?

1 Answer available

What is your preferred neoadjuvant chemotherapy regimen for muscle invasive bladder cancer, adequate performance status and preserved kidney function?

2 Answers available

Do you offer adjuvant chemotherapy to patients with urachal adenocarcinoma and at least one high risk feature?

e.g. lymph node metastasis, presence of tumor involving the peritoneal surfaces and/or the abdominal wall. If so, which regimen would you offer?

1 Answer available

What type of surveillance plan should one use to follow a young person after orchiectomy for a >3cm pure mature teratoma of the testicle?

1 Answer available

Would you continue bleomycin in a patient with intermediate risk stage 3B nonseminona who had a pulmonary embolism?

2 Answers available

What is your preferred treatment for patients with painful gynecomastia on anti-androgen therapy for prostate cancer?

1 Answer available

Would you skip adjuvant RT in post prostatectomy patients?

Based on the RADICALS-RT trial presented at ESMO, can RT be omitted in post op prostate patients in favor of salvage RT? If not which group of patient...

6 Answers available

Is there a preferred sequence of therapy in renal cell carcinoma?

For example, is there any data to suggest a benefit to starting with immunotherapy prior to TKI or the alternative?

1 Answer available

In patients with metastatic RCC who have had a complete response to pembrolizumab and axitinib and undergone a nephrectomy, how long would you continue therapy post-operatively?

Would you treat until progression or for a defined "adjuvant" course after nephrectomy?

1 Answer available

Would you retreat a patient with docetaxel for metastatic castrate resistant prostate cancer if treated in hormone sensitive setting (metastatic disease) with good response three years ago but now has CRPC and has progressed on abiraterone?

1 Answer available

How would you treat a residual mediastinal mass in patients with a mediastinal germ cell tumor with an incomplete response to primary chemotherapy with BEPx4?

i.e. gross disease on scans that is too diffuse to be removed completely and/or decreasing but not normal markers Do you pursue close surveillance, s...

1 Answer available

How would you treat a patient with metastatic Leydig cell tumor of the testes with extensive lung and abdominal metastases (peritoneum, retroperitoneal LN and soft tissue) following orchiectomy and maximal surgical resection of abdominal disease?

1 Answer available

Is there any role for "adjuvant" therapy for completely resected oligometastatic RCC?

1 Answer available

What duration of ADT do you recommend for patients with high risk or very high risk prostate cancer who undergo radical prostatectomy, adjuvant RT, and adjuvant docetaxel?

1 Answer available

Do you check baseline or surveillance audiometry (if not overtly symptomatic) to screen for hearing loss in all patients getting cisplatin?

3 Answers available

For a very high risk prostate cancer with relatively no elevation in PSA but no distant or nodal metastasis would you consider “neoadjuvant” ADT and chemotherapy prior to EBRT?

In this case, Gleason 5+5 in all cores, clinical T4.

1 Answer available

In a patient with intermediate risk castration sensitive prostate cancer S/P prostectomy and now with biochemical recurrence + regional lymph node involvement 8 months post RP, would you do hormonal therapy (ADT or ADT+Abiraterone) with or without EBRT?

1 Answer available

Should enzalutamide be given concurrently with Sip-T in castration-resistant metastatic prostate cancer?

2 Answers available

How would you treat a patient with poorly differentiated carcinoma with squamous differentiation of the kidney following nephrectomy with metastatic retroperitoneal adenopathy?

2 Answers available

How do you mitigate the risk of hearing loss for patients requiring cisplatin?

Specifically, would you consider utilizing sodium thiosulfate in adults based on the pediatric data from Brock et al. NEJM 2018?

1 Answer available

In a patient with intermediate risk metastatic RCC with high thrombotic tumor burden in the IVC extending to the right atrium, is there any clinical or biologic rationale to guide choice of therapy between axitinib/pembrolizumab vs nivolumab/ipilimumab?

3 Answers available

Do you routinely use tumor lysis prophylaxis when starting chemotherapy for germ cell tumors?

How do you assess risk of tumor lysis syndrome, and is hydration sufficient or should hypouricemic agents be used as well?

2 Answers available

Is there a substitution for etoposide you would recommend for testicular cancer patients who need multiple cycles of BEP?

Given the national shortage of etoposide starting in February 2018?

2 Answers available

How do you treat metastatic urothelial carcinoma after progression on immune checkpoint inhibitor?

No actionable mutation on NGS testing. What approved therapy do you prefer? Are there specific investigational agents currently in clinical trial...

1 Answer available

Would you treat a patient with ESRD on hemodialysis and penile cancer with neoadjuvant ifosfamide?

What would be a safe dose for ifosfamide and how would you time with HD? Alternatively, would you recommend a different regimen? What about using neoa...

1 Answer available

What is the preferred chemotherapy regimen for a patient with bladder adenocarcinoma with signet ring features?

1 Answer available

How do you manage androgen deprivation in a patient with oligometastatic prostate cancer in which the primary and all known metastatic sites have been treated with curative intent radiation and PSA remains undetectable?

How long would you continue androgen deprivation after radiation?

2 Answers available

Are the cardiac risks of LHRH agonists also seen in patients undergoing bilateral orchiectomy for ADT in hormone-sensitive prostate cancer?

1 Answer available

Is there a lung metastasis size cut-off do you suggest for selecting between BEP and VIP as initial chemotherapy in advanced testicular cancer?

UpToDate indicates that VIP is an alternative to BEP for men who are not candidates for bleomycin, and that one criteria for not being such a candidat...

2 Answers available

Has the role of radium-223 changed in the treatment of prostate cancer given the availability of newer anti-androgen medications to treat metastatic prostate cancer?

2 Answers available

Do you offer adjuvant chemotherapy or abiraterone for patients with high and very high risk prostate cancer with still detectable PSA after RP and LN dissection?

1 Answer available

Would you consider adding IO therapy to 1st-line platinum/etoposide in a patient with metastatic extrapulmonary small cell carcinoma?

Patient has small cell carcinoma of the bladder with extensive hepatic metastases. Would you extrapolate the approach from IMpower133?

1 Answer available

Would you prefer FGFR inhibitor or second line immunotherapy in a patient with metastatic urothelial cancer of the bladder with FGFR mutation?

Retrospective data show very low response rate of immunotherapy in FGFR mutated patients.

2 Answers available

Do you offer bladder-sparing approaches as an alternative to cystectomy for surgery-eligible patients with muscle-invasive bladder cancer?

Should cystectomy remain standard of care? (Recently debated in JAMA Oncology: http://jamanetwork.com/journals/jamaoncology/article-abstract/2520055...

1 Answer available

How would you treat a patient with metastatic castration resistant prostate adenocarcinoma with progressive neuroendocrine differentiation?

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

1 Answer available

What adjuvant treatment would you use for a cisplatin ineligible, node positive, upper tract urothelial cancer patient after radical nephroureterectomy?

1 Answer available

How do you treat a patient who develops metastatic prostate CA while on enzalutamide or apalutamide for originally M0 CRPC?

1 Answer available

How would you approach definitive nonsurgical management for biopsy-proven, localized small cell carcinoma of the prostate?

Would you give chemotherapy concurrently with radiation? Would you change your radiation dose?

2 Answers available

Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

4 Answers available

How would you approach a patient with Gleason 9 prostate cancer and regional lymphadenopathy as well as inguinal lymphadenopathy (M1a) but no bone metastases?

Would you offer definitive management with radiation and ADT? Or systemic therapy alone such as with ADT+abiraterone?

2 Answers available

Is immunotherapy the next best option for a patient with metastatic translocation-associated renal cell carcinoma (TFEB rearrangement) after progression on 1st line sunitinib and 2nd line everolimus/lenvatinib?

Mixed opinions about efficacy of IO therapy in this subtype.

3 Answers available

Which patients with metastatic hormone sensitive prostate cancer would you treat with enzalutamide or apalutamide (instead of abiraterone or docetaxel)?

ENZAMET and TITAN trials published at ASCO 2019 show benefit to both 2nd generation AR antagonists when compared to placebo but wondering how this wil...

2 Answers available

In refractory germ cell tumor, in the absence of results of the randomized TIGER trial, how do you determine if patients should be treated with conventional-dose chemotherapy versus high-dose chemotherapy?

What factors do you consider to aid in this decision making? The TIGER trial is a prospective randomized trial comparing these approaches.

1 Answer available

How would you approach first-line treatment in a young patient with VHL with intermediate/poor risk metastatic clear cell RCC?

Is there any data as to whether TKI or immunotherapy is more effective in this population?

1 Answer available

What is your preferred first-line therapy for patients with newly diagnosed intermediate- or poor-risk metastatic clear cell RCC?

Some considerations: -Cabozantinib (Based on CABOSUN trial, NCCN does not list this as a Category 1 recommendation)-Nivolumab + Ipilimumab (CheckMate...

3 Answers available

When do you consider using high dose IL-2 in patients with mRCC?

Are there any patient and/or pathologic features that would lend you to considering IL-2 over other approved I/O or TKI therapies?

2 Answers available

How do you treat metastatic collecting duct carcinoma of the kidney in the first line setting?

2 Answers available

How do you treat metastatic renal cell carcinoma with unclassified histology without sarcomatoid features?

I have seen the question regarding treatment of non-clear cell RCC in general: https://www.themednet.org/question/3934. Is there any data or experienc...

1 Answer available

How do you manage venous thromboembolic events or bleeding events in RCC or HCC patients on anti-angiogenic TKIs?

Arterial events have clear instructions to permanently discontinue on the FDA label. Especially in HCC without many other treatment options, giv...

1 Answer available

How many cycles of docetaxel do you give to patients with metastatic castration resistant prostate cancer?

1 Answer available

Do you use cabozantinib preferentially over other TKIs in mRCC patients who have progressed on immunotherapy with primary metastatic burden being bony disease?

1 Answer available

How do you manage significant fatigue caused by androgen deprivation therapy in prostate cancer patients?

1 Answer available

Is it safe to deliver SBRT to progressive lung metastases to patients with metastatic RCC receiving concurrent pazopanib?

2 Answers available

Would you use enzalutamide concurrently in combination with radium-223?

In light of the data from ERA223 showing increased deaths and fractures with the combination of radium-223 and abiraterone compared to abiraterone alo...

1 Answer available

For a patient with metastatic castration-resistant prostate cancer to the bones with rising PSA but no evidence of radiographic or symptomatic progression, would you continue with the same treatment or change therapy based on biochemical progression?

Assuming there was an initial period of response to the mCRPC treatment.

1 Answer available

Would you use abiraterone or docetaxel in addition to ADT and radiotherapy for patients with very high risk, node-negative prostate cancer?

1 Answer available

What chemotherapy regimen is best suited for patients with platinum-refractory metastatic bladder cancer who have good or excellent performance status?

2 Answers available

Do you recommend prostate RT for patients with metastatic (M1) disease?

A recent NCBD analysis (Rusthoven et al, JCO 2016) suggests that the addition of prostate RT significantly improves survival compared to ADT alon...

8 Answers available

Would you add atezolizumab to carboplatin + etoposide for small cell/neuroendocrine prostate cancer?

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

1 Answer available

How do you manage surveillance imaging for patients with metastatic castration-resistant prostate cancer?

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

1 Answer available

What chemotherapy regimen would you give for metastatic adenocarcinoma that arose from teratoma/germ cell tumor?

Late relapse, previously treated with BEP 30 years ago.

1 Answer available

Would you recommend starting treatment for a renal cell carcinoma patient with new low-burden, asymptomatic sub-centimeter bilateral pulmonary nodules that arise after a short disease-free interval (<6 months) after nephrectomy for stage I disease?

Would you consider treatment based upon imaging alone or would you wait for tissue confirmation of metastatic disease?

3 Answers available

How do you decide between abiraterone or docetaxel for first line treatment of newly diagnosed metastatic prostate cancer?

Given that ADT + abiraterone and ADT + docetaxel have not been directly compared.

1 Answer available

How would you treat a patient with biopsy-proven recurrent urothelial bladder cancer with M1a disease (limited to retroperitoneal nodal disease)?

NCCN guidelines suggest systemic therapy only or concurrent chemoradiotherapy. What is your approach?

1 Answer available

How do you treat newly diagnosed low volume metastatic hormone sensitive prostate cancer in light of new data from STAMPEDE presented at ESMO 2018?

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

1 Answer available

How do you manage hot flashes in men with prostate cancer on androgen deprivation therapy?

7 Answers available

In view of possible equivalent efficacy of low dose abiraterone with food, has anyone had clinical experience offering low dose abiraterone to spare patients from financial toxicity of abiraterone?

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

1 Answer available

Is it acceptable defer or forgo biopsy and to start androgen deprivation therapy in an elderly, fragile patient with PSA in the 900s and evidence of bone metastases?

1 Answer available

Is it unusual to have isolated LDH elevation and normal HCG and AFP in non-seminomatous germ cell tumor (embryonal carcinoma)?

In a patient s/p orchiectomy and with pelvic lymphadenopathy, would you consider lymph node biopsy to confirm involvement by non-seminomatous germ cel...

2 Answers available

What is your approach to metastatic non-clear cell RCC?

Most of the studies have excluded non clear cell histologies. If you use a similar approach to clear cell, have you seen similar responses?

1 Answer available

When is the best time to start denosumab in men with metastatic prostate cancer?

Should it be started at the initial diagnosis of bone mets?

2 Answers available

How do you approach non-metastatic castration-resistant prostate cancer?

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

2 Answers available

Would you use apalutamide in high risk non-metastatic castrate resistant prostate cancer?

The recent SPARTAN trial showed a remarkable improvement in metastasis free survival and many other secondary endpoints except the lack of significant...

1 Answer available

How would you approach a patient with M0 castrate-resistant prostate cancer started on enzalutamide who continues to have increasing PSA levels without metastases seen on imaging?

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

1 Answer available

How would you approach risk-stratification/staging of a extra-gonadal germ cell tumor with both mediastinal and retroperitoneal lymphadenopathy?

Is there any role for orchiectomy in this setting?

1 Answer available

How do you manage patients with bilateral renal cell carcinomas?

What are the special considerations in the non-metastatic setting vs metastatic setting?

1 Answer available

How do you manage a patient with metastatic prostate cancer who does not acheive a PSA response to upfront ADT?

1 Answer available

How do you approach a patient with a non-castrate testosterone level and rising PSA despite receiving LHRH agonist therapy?

1 Answer available

How would you approach management of a large retroperitoneal mass that shows seminoma on biopsy?

Testicular ultrasound, CT, and tumor markers are without abnormalities outside of the mass.

2 Answers available

Is there any data on the use of PARP inhibitors in patients with metastatic urothelial carcinoma with deleterious DDR mutations?

1 Answer available

Is there a role for DDR gene mutation or tumor mutation burden/load in predicting response to immunotherapy in urothelial cancer?

1 Answer available

How do you choose among the available PD-1/PDL-1 inhibitors approved for metastatic bladder cancer?

There are now five PD-1/PDL-1 inhibitors approved for metastatic bladder CA, one (Atezolizumab) as first-line therapy in cisplatin-ineligible patients...

2 Answers available

In light of the recently published CARMENA trial, is there still a role for cytoreductive nephrectomy in metastatic RCC patients?

1 Answer available

How would you approach locally advanced bladder cancer in a patient on hemodialysis?

What systemic therapy do you use? Do you incorporate any multi-modality therapies?

1 Answer available

Would you use AR-V7 testing to decide second-line androgen receptor-axis-targeted therapy vs chemotherapy for patients who with metastatic castration-resistant prostate cancer?

If yes, what factors push you to test for AR-V7 or would you test all patients in this clinical scenario?

3 Answers available

What approach would you take for patients with metastatic castration-resistant prostate cancer with marked PSA response (undetectable) on docetaxel, but radiographic progression in bone metastases?

1 Answer available

How would you treat a patient with high-volume metastatic prostate cancer who has asymptomatic biochemical relapse after having a good response to upfront docetaxel?

Would you initiate abiraterone or enzalutamide for the rising PSA or wait until the patient is symptomatic or has a new site of metastasis?

1 Answer available

What is your preferred first line therapy for metastatic sarcomatoid renal cell carcinoma?

2 Answers available

What palliative systemic treatment options (if any) may be considered for metastatic adenocarcinoma of the rete testis?

1 Answer available

For patients with high-risk metastatic castration-sensitive prostate cancer who have completed upfront ADT + docetaxel, would you consider starting abiraterone or enzalutamide in addition to ADT while the disease is still castration-sensitive?

Are there particular populations in whom you would add an AR targeted agent after docetaxel?

3 Answers available

What is your approach to solitary node positive bladder cancer (e.g. N1) in a patient who is otherwise a candidate for either bladder preservation or radical cystectomy?

Current NCCN guidelines seem to support a variety of approaches.

1 Answer available

Is there a role for any non-cisplatin based adjuvant therapy or radiotherapy (in absence of platinum sensitizer) for muscle-invasive, node-negative bladder cancer after radical cystectomy?

The patient is cisplatin ineligible due to renal dysfunction.

1 Answer available

How do you approach patients with biochemical relapse of high-risk prostate cancer, with PSA doubling time less than 6 months?

Pt previously treated with radical prostatectomy and adjuvant radiotherapy. If recommending therapy, what is the role of concurrent abiraterone + AD...

1 Answer available

Do you treat patients with metastatic renal cell carcinoma who progress on first-line TKI with single agent nivolumab or the combination of nivolumab plus ipilimumab?

Based on new FDA approval of nivolumab plus ipilimumab in the first-line setting for intermediate- and poor-risk disease, would you give the combinati...

1 Answer available

What would you recommend for pTa, stage 0a papillary urothelial carcinoma of the distal ureter?

Could observation and serial cystoscopy be a reasonable option or is surgery necessary? If recommending surgery, can a procedure less than a nephroure...

1 Answer available

How do you manage patients with locoregional lymph node recurrence after radical cystectomy for muscle invasive bladder cancer?

1 Answer available

For patients with muscle-invasive bladder cancer and borderline renal function, would you consider use of a split-dose cisplatin/gemcitabine regimen for neoadjuvant treatment?

2 Answers available

Would you consider use of single-agent lenvatinib for advanced renal cell cancer after first-line therapy?

Data reported by Motzer et al Lancet 2015 demonstrated a statistically superior PFS benefit of lenvatinib monotherapy over everolimus alone. In partic...

2 Answers available

How do you decide which tyrosine kinase inhibitor (sunitinib, pazopanib, cabozantinib) to use in the first-line setting for newly diagnosed metastatic RCC?

1 Answer available

If a patient with a germ cell tumor has such an event thrombotic events on BEP, is it safe to re-challenge with BEP therapy?

3 Answers available

How do you approach a patient with inoperable urothelial carcinoma of the bladder with persistent non-muscle invasive disease despite intravesical BCG/IFN and intravesical chemotherapy?

Would you recommend radiation and/or systemic therapy? If you would irradiate, what would your fields/volumes look like?

1 Answer available

Do you see a role for adjuvant sunitinib after resected RCC?

Recent evidence has been mixed, with no DFS or OS benefit in 1 trial (ASSURE, Haas et al, Lancet 2016) and DFS benefit in another (S-TRAC, Ravaud et a...

3 Answers available

Do you find the measurement of ultra-sensitive PSA provides clinical benefit in a patient with biochemical recurrence after radical prostatectomy compared to non ultra-sensitive PSA measurement?

1 Answer available

What alternative therapies would you consider for a patient with metastatic castration-sensitive prostate cancer who declines GnRH analogues?

Is there a treatment that you prefer for such patients?

1 Answer available

Would you consider a trial of pembrolizumab in a patient with metastatic urothelial carcinoma progressing on atezolizumab?

Given the apparently stronger results from KEYNOTE 052 (pembrolizumab) compared to IMvigor 211 (atezolizumab), would you consider pembrolizumab for pa...

2 Answers available

Would you consider concurrent chemoRT for unresectable bladder adenocarcinoma?

The current treatment for bladder adenoCA is surgery. However in non-surgical candidates, RT is an option. Would you consider adding chemo ? Also woul...

1 Answer available

Would you consider neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer who are cisplatin-ineligible?

If so, what chemotherapy regimen would you use? If not, what management options would you generally recommend?

1 Answer available

Is there a role for neoadjuvant chemotherapy or abiraterone for a young man with very high risk prostate cancer without imaging evidence of metastasis?

For example in a <50 years old man with Gleason 9, PSA > 50 disease?

1 Answer available

What is the role of liquid biopsy in patients with metastatic castration resistant prostate cancer to asses BRCA1/2 mutations and consider off-label PARP inhibitors?

Alternatively, would a biopsy of a metastatic bone lesion be preferred in a patient who has already progressed on chemo and hormonal therapy?

2 Answers available

When in the treatment algorithm are you incorporating targeted sequencing of metastatic prostate cancer?

Given the FDA breakthrough therapy designation for olaparib in BRCA1/2 and ATM mutated mCRPC, when do you sequence mCRPC? Do you have a preferred...

2 Answers available

Do you consider MSI testing for mCRPC?

Based on 2-3% MSH2 mutation and 1% MLH1 mutation rates in metastatic disease regardless of castration sensitivity, should we be looking for this earli...

2 Answers available

In patients with good performance status, metastatic clear cell kidney cancer, and minimal metastatic disease, would you consider nephrectomy or partial nephrectomy if there are mets to brain?

1 Answer available

Is it appropriate to re-consider bladder preservation in patients with bladder muscle invasive cancer (T2) who was initially poor candidate for BP (multifocal disease etc.) but had complete response after neoadjuvant chemotherapy.?

Would you offer definitive radiation/chemoradiation if he is refusing cystectomy?

2 Answers available

Is there utility in molecular or proteomic testing (e.g., Foundation or Caris) for metastatic clear cell renal cell carcinoma when several lines have failed?

1 Answer available

Would you consider local therapy (e.g. XRT) in patients with mRCC with oligometastatic disease progression?

If current systemic treatment is otherwise controlling the disease and is well-tolerated, is there value to locally aggressive therapy in an attempt t...

1 Answer available

In light of the STAMPEDE data on the addition of docetaxel or abiraterone, what is now your initial treatment for young, healthy men with high-grade prostate cancer (Gleason 9-10) with relatively asymptomatic metastatic castration-sensitive disease?

2 Answers available

How do you manage musculoskeletal pain in men receiving androgen deprivation therapy for non-metastatic prostate cancer?

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

1 Answer available

In light of the recent results from STAMPEDE and LATITUDE, to which patients with newly diagnosed metastatic prostate cancer are you offering up-front abiraterone vs. up-front docetaxel?

Pending head-to-head comparisons, do you believe there are any subgroups who might benefit more from one or the other?

2 Answers available

For patients who have completed up-front docetaxel for metastatic castration-sensitive prostate cancer, should they proceed to abiraterone before the development of castration resistance?

Two recent studies show benefit to up-front abiraterone for metastatic castration-sensitive prostate cancer, although these studies used control arms ...

2 Answers available

When would you recommend abiraterone concurrently with RT for high-risk prostate cancer?

Are the results of the STAMPEDE trial presented at ASCO 2017 practice changing?

3 Answers available

If a patient with non-metastatic prostate cancer is found to have a BRCA mutation, should this influence treatment recommendations for local therapy?

2 Answers available

How do you manage a patient with a history of non-seminomatous germ cell tumor who has a rising AFP after primary chemotherapy without any imaging evidence of recurrence?

Given the non-specific nature of AFP and its elevation in various benign conditions, is there an AFP cutoff level or change over time for which you wo...

1 Answer available

When do you consider for first-line atezolizumab for metastatic bladder cancer?

Which patients do you consider to be chemotherapy-ineligible for the sake of this treatment decision? How strong does the contraindication need to be?

1 Answer available

How do you choose which LHRH agonist or antagonist to prescribe for ADT in patients with prostate cancer?

What clinical considerations factor into your decision to choose leuprolide vs goserelin vs triptorelin vs degarelix, etc?

1 Answer available

What surveillance strategy do you use for patients after resection of localized renal cell cancer?

NCCN guidelines offer suggested schedules for interval imaging and laboratory studies, but also make it clear that the quality of evidence for these r...

1 Answer available

Would you consider a trial of anti-PD-1 therapy following disease progression through anti-PD-L1 therapy for advanced urothelial carcinoma?

1 Answer available

How do you sequence abiraterone and enzalutamide in metastatic, castrate-resistant prostate cancer?

What determines which you select first? How do concerns about cross-resistance factor in after progression on one of these agents?

3 Answers available

Are there contraindications to giving radium-223 concurrently with palliative radiotherapy or systemic chemotherapy for mCRPC?

To what extent do you worry about overlapping myelosuppression? Is there any advantage to overlapping therapy?

1 Answer available

How do you approach isolated recurrence in a para-aortic lymph node following definitive radiation for localized prostate cancer?

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...

1 Answer available

Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

3 Answers available

When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

1 Answer available

What is your preferred second-line agent for treatment of metastatic urothelial carcinoma?

And how should we compare checkpoint inhibitors? Given the FDA approval of atezolizumab and nivolumab as second-line agents for metastatic urothe...

1 Answer available

Do you ever consider intermittent ADT for metastatic prostate cancer?

The Intergroup 0162 trial did not demonstrate noninferiority, although OS difference only 5.1 vs. 5.8 yrs. Would pattern of spread affect your d...

1 Answer available

How would you approach adjuvant therapy for a finding of carcinosarcoma in a prostatectomy specimen?

2 Answers available

How would you manage positive surgical margins after partial nephrectomy for kidney cancer?

When would you use surveillance versus repeat excision or adjuvant systemic or local therapy?

2 Answers available

Would you consider first-line cabozantinib in patients with intermediate- or poor-risk mRCC?

The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib.

1 Answer available

How would you treat a patient with widely metastatic clear cell RCC who has undergone craniotomy/resection of a single brain metastasis?

In the setting of recent craniotomy and a plan for SRS to the surgical cavity, which systemic therapy would you choose and when would you&nb...

2 Answers available

For patients with seminoma testicular cancer who are Stage II (positive retroperitoneal lymph nodes), what factors do you consider when choosing between radiation versus chemotherapy?

1 Answer available

Would you treat a muscle invasive urethral recurrence of bladder cancer with definitive chemoradiation?

For a patient with a history of non-muscle invasive disease in the bladder, presenting with a prostatic urethra only recurrence, do you approach this ...

1 Answer available

Is there any role for re-challenge with enzalutamide or abiraterone after prior failure in metastatic castrate-resistant prostate cancer?

1 Answer available

How do you approach management of locally-advanced, unresectable, but non-metastatic bladder cancer?

When do you offer trimodality bladder-sparing approaches? Is there any role for starting standard neoadjuvant therapy in an attempt to convert to rese...

1 Answer available

How do you approach prostate cancer patients with persistent obstructive lower urinary tract symptoms after primary radiation therapy?

Or in patients with metastatic disease on ADT who have not had primary therapy? In what situations do you consider palliative prostatectomy?

1 Answer available

What is your approach to treating metastatic prostate cancer with primary resistance to GnRH analogues or early CRPC?

After confirming castration levels of testosterone, is the next best step to add docetaxel (as in CHAARTED and STAMPEDE, although not explicitly for G...

1 Answer available

In a patient with a history of treated stage II seminoma with rising bHCG while on surveillance, do you routinely recheck the bHCG with a different assay?

When are you concerned for a false positive? FDA guidelines include a suggestion to try another assay in case heterophile antibodies are causing a fal...

1 Answer available

For patients with widespread bony metastases from prostate cancer, do you ever consider treating with beta-emitters such as Samarium-153 or Strontium-89 over Radium-223?

Radium-223 has an overall survival benefit and lower hematologic toxicity, but at a significantly increased cost. Does the cost-effectiveness fa...

1 Answer available

For patients with RCC who respond to PD-1 blockade, do you ever discuss stopping treatment?

If so, at what point? McDermott et al. demonstrated some lasting responses after discontinuation of therapy (JCO 2015), but these responses are s...

4 Answers available

How do you counsel men with prostate cancer on the cardiovascular risks of androgen deprivation therapy?

How might a recent (within 6 months) myocardial infarction affect your recommendations?

1 Answer available

For patients who develop oligometastatic renal cell carcinoma amenable to local therapies (i.e. ablation, radiation therapy, or surgery), how do you integrate systemic therapy, if at all?

For patients who developed oligometastases while off systemic treatment, do you start systemic therapy following local therapy or return to active sur...

2 Answers available

When do you use high-dose IL-2 for metastatic renal cell carcinoma?

Are there circumstances when you would choose IL-2 over checkpoint inhibitor trials or TKIs for fit patients? How should IL-2 be sequenced with these ...

1 Answer available

How to you treat patients with germ cell tumors that progress during treatment with first-line platinum-based chemotherapy (i.e. platinum-refractory disease)?

1 Answer available

How do you approach treatment options for men with germ cell tumors that relapse within 2 years of initial chemotherapy?

In which circumstances should high-dose chemotherapy with autologous stem cell transplant be considered, versus second-line chemotherapy regimens or c...

1 Answer available

Is there a role for atezolizumab as a first-line agent for metastatic urothelial carcinomas?

Based on the abstract from IMvigor 210 presented at ASCO this year, are you offering atezo to patients who otherwise may not tolerate platinum-based c...

1 Answer available

Do you consider use of TIP as first-line therapy for poor-risk advanced germ cell tumors?

Based on a recent single-arm phase II trial, is there a role for paclitaxel, ifosfamide, and cisplatin (TIP) as a first-line regimen instead of BEP?

1 Answer available

What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?

Do other factors (i.e. Gleason score, pretreatment PSA, or pT stage) affect your decision?

2 Answers available

In light of CHAARTED and STAMPEDE, should all men with newly-diagnosed, treatment-naive metastatic prostate cancer be treated with chemohormonal therapy?

1 Answer available

Which, if any, aspects of your management of prostate cancer differ in your African-American patients versus those of other racial/ethnic backgrounds?

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

1 Answer available

How do you decide when to refer a patient with metastatic renal cell carcinoma for cytoreductive nephrectomy?

1 Answer available

What is your preferred third-line treatment for a patient with metastatic renal cell carcinoma who has had progression of disease on both initial VEGFR-TKI therapy and second-line nivolumab?

For patients who remain fit and interested in treatment, but for whom a clinical trial is not an option, what systemic therapy do you reach for in thi...

3 Answers available

Do you use denosumab only for castration-resistant metastatic prostate cancer involving bone, or also castration-sensitive disease?

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

1 Answer available

For patients eligible for and considering active surveillance for low-risk prostate cancer, do you routinely use tests for molecular risk stratification?

Are there specific subsets for whom these results should change management?

1 Answer available

Do you routinely offer AR-v7 testing to determine whether to treat with chemotherapy versus enzalutamide or abiraterone in metastatic castration resistant prostate cancer?

2 Answers available

Do you routinely include sipuleucel-T as one of your lines of systemic therapy for metastatic castration resistant prostate cancer?

If so, how do you sequence this with other therapies? In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

1 Answer available

Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

1 Answer available

For a patient with metastatic urothelial cancer who has progressed on platinum-based chemotherapy, do you test for tumor PD-L1 expression prior to choosing atezolizumab as second-line treatment?

In the IMvigor 210 trial, increased PD-L1 expression in patients’ tumors was associated with response to atezolizumab, but some patients whose t...

1 Answer available

For castration-naive metastatic prostate cancer patients who you plan to treat with LHRH agonist monotherapy, how long do you treat with an anti-androgen therapy prior to and after initiating the LHRH-agonist?

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

1 Answer available

Is there a role for neoadjuvant chemotherapy in upper-tract urothelial carcinoma?

Since the benefit of neoadjuvant chemotherapy is well-defined in muscle-invasive bladder cancer, is it reasonable to consider this in upper-tract tumo...

1 Answer available

Is there a role for adjuvant docetaxel in patients with high-risk localized prostate cancer who elect for prostatectomy?

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521. Following prostatectomy,...

1 Answer available

Following presentation of the PRINCE at ASCO 2016, should we be offering intermittent docetaxel to patients with metastatic castration-resistant prostate cancer?

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

1 Answer available

When should intermittent androgen deprivation vs continuous androgen deprivation be used for the treatment of prostate cancer?

In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

1 Answer available

Is there any role for radium-223 early in the course of castration-resistant prostate cancer with bone metastases?

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies. Is there a population of men w...

1 Answer available

For high risk, stage I, non-seminomatous testicular germ cell tumors, are there particular circumstances under which RPLND is clearly preferred over chemotherapy or surveillance?

Is any amount of teratoma or PNET an indication for surgery?

1 Answer available

Is a carboplatin-based regimen a reasonable alternative for patients with muscle-invasive bladder cancer who are not eligible for neoadjuvant cisplatin-based chemotherapy?

1 Answer available

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?

1 Answer available

At what point would Radium-223 dicholoride treatment be the best management for a patient with established metastatic prostate cancer with an elevated PSA and symptomatic bone pain with corresponding bone lesions on imaging?

1 Answer available

Is weekly Cisplatin considered a valid alternative to Cisplatin cycles every 3 weeks as part of definitive chemo-radiation for muscle invasive bladder cancer?

1 Answer available

How do you approach muscle invasive bladder cancer in an elderly patient who cannot tolerate chemotherapy?

Do you favor a short palliative regimen, or a full course definitive treatment to 64.8Gy? How does your management change if the patient has a good pe...

1 Answer available

When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

3 Answers available

Should patients with muscle invasive node negative bladder cancer wishing to have bladder preservation receive chemoRT alone or neoadjuvant chemotherapy followed by chemoRT?

Assuming a patient who could tolerate either, which is preferred? Does this depend on the choice for concurrent chemotherapy (5FU+mitomycin vs ci...

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Lancet, 2016 Mar 19

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Eur. Urol.,

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Radiother Oncol, 2006 Oct

Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Eur Urol, 2015 Jul 16

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

BJU Int, 2009 Feb

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

European urology, 2014-06

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

The New England journal of medicine, 2013-07-18

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

The New England journal of medicine, 2004-10-07

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

JAMA oncology, 2016-11-01

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

J. Nucl. Med., 2015 Jun 25

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

Lancet Oncol., 2010-02-01

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

The Journal of urology, 2005-08

Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

The Journal of urology, 2002-09

Impact of previous local treatment for prostate cancer on subsequent metastatic disease.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Nature, 2005-12-08

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

J Clin Oncol, 1999 Jul

Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.

Lancet, 2015 Jan 3

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.

The New England journal of medicine, 2001-12-06

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Lancet, 2001-09-22

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Breast Cancer Res. Treat., 2010-02-01

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

The Journal of urology, 1982-06

Treatment of a metastatic prostate derived tumor with surgery and chemotherapy.

Cancer research, 2000-04-15

Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction.

J. Clin. Oncol., 2009-04-01

Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.

Oncol. Rep., 2015-12-01

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.

Nat Commun, 2015-04-01

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

PLoS ONE, 2016-01-01

Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

J. Urol., 2002-04-01

Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.

European urology, 2018-02

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Lancet, 2018 Oct 18

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Indian J Urol,

Severe acute tumor lysis syndrome in patients with germ-cell tumors.

The Lancet. Oncology, 2006-06

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Lancet (London, England), 2016-05-07

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

JAMA oncology, 2016-04

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

JAMA oncology, 2017-01-01

Association Between Androgen Deprivation Therapy and Risk of Dementia.

JAMA, 2009-08-26

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

European urology, 2015-05

Adverse effects of androgen deprivation therapy and strategies to mitigate them.

JAMA, 2008-01-23

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-02-01

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

Journal for immunotherapy of cancer, 2015

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Cancer immunology, immunotherapy : CII, 2016-08

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995-03

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

The cancer journal from Scientific American, 2000-02

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

Cancer immunology, immunotherapy : CII, 2016-12

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Urologic oncology, 2015-11

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.

Lancet (London, England), 2016-05-14

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

The New England journal of medicine, 2016-12-08

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

JAMA oncology, 2017-09-01

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

Canadian Agency for Drugs and Technologies in Health, 2016-10-31

Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines

Medicine (Baltimore),

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.

Future Oncol, 2015 Oct 05

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

JCO Precision Oncology, 2017 May 31

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

The New England journal of medicine, 2016-08-04

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Prostate cancer and prostatic diseases, 2014-09

Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

Future Challenges for Drug Development in Renal Cell Carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

The New England journal of medicine, 2017-03-16

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

The New England journal of medicine, 2018-04-12

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine, 2018-06-28

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

European urology, 2012-04

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

European urology, 2014-07

Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

N. Engl. J. Med., 2012-04-19

Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

J. Urol., 2007-09-01

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.

J. Clin. Oncol., 2006-05-20

Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-07-10

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

The New England journal of medicine, 2015-08-20

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Lancet (London, England), 2017-01-07

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Oncology, 2013-01-01

Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.

PLoS ONE, 2015-01-01

Gynecomastia in Patients with Prostate Cancer: A Systematic Review.

Ann. Oncol., 2018 Feb 26

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Urologe A,

[A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].

J Clin Oncol, 1998 Nov

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.

Nature medicine, 2017-06

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Oncotarget, 2016-08-16

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Clinical genitourinary cancer, 2018-08

Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Urology, 2013-06

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-10

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Nat Rev Urol, 2014 Apr

Small cell carcinoma of the prostate.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

N. Engl. J. Med., 2018 Jun 03

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Nature, 2013-07-11

Mutational heterogeneity in cancer and the search for new cancer-associated genes.

The New England journal of medicine, 2015-10-29

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med, 2010 Jul 29

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

The Lancet. Oncology, 2016-03

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

European urology, 2016-05

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

Clinical genitourinary cancer, 2017-12

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

Prostate Int,

Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Low-Fat Abiraterone Food Effect Is of Little Consequence.

Nat Rev Urol, 2017 Dec 12

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Journal for immunotherapy of cancer, 2018-01-29

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-10

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-04

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.

The Lancet. Oncology, 2016-07

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2018-04-05

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Ann. Oncol., 2013 Nov 04

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.

Lancet Oncol., 2013 Jan 08

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

N. Engl. J. Med., 2019 Jun 02

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N. Engl. J. Med., 2019 May 31

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

JAMA Oncol,

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

The Lancet. Oncology, 2019-03

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-20

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Br. J. Cancer,

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-04

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

The New England journal of medicine, 2019-03-21

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Urology, 2007-02

Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.

Case Rep Urol, 2013 May 08

Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy.

BJU international, 2012-10

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

European urology, 2018-08

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-12-20

Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor.

Annals of oncology : official journal of the European Society for Medical Oncology, 2010-04

Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy.

Eur. Urol., 2018 Jul 03

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

The New England journal of medicine, 2003-08-28

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Lancet,

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

JAMA Oncol, 2018 Nov 1

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.

Lancet, 2019 Apr 11

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

J. Clin. Oncol., 2017 Dec 14

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Eur. Urol., 2019 Jul 19

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

The Lancet. Oncology, 2017-11

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Ann. Oncol.,

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.

J. Clin. Oncol., 2011 Dec 12

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

European urology focus, 2019-11

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Obstet Gynecol, 2009-09-01

Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial.

J. Clin. Oncol.,

Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.

Lancet, 2008 Dec 16

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Lancet, 2011-12-17

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Eur. Urol., 2016 Mar 17

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.

J Thorac Oncol. , 2019 Oct 17

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

Eur Urol Oncol, 2019 Oct 08

What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review.

Eur. Urol., 2019 Sep 26

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Cancer, 2020 Feb 19

Validation of a subclassification for high-risk prostate cancer in a prospective cohort.

Eur. Urol., 2020 Jan 17

Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.

JAMA Netw Open, 2020 Feb 05

Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.

Chest, 1997-03

Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.

J. Clin. Oncol.,

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Clin Genitourin Cancer, 2017 Sep 04

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.

Eur. Urol., 2020 Jan 01

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.

Journal of the National Cancer Institute, 2005-09-21

Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.

Eur. J. Cancer,

Incidence of second primary cancer following testicular cancer.

Br. J. Cancer, 2007 Jan 30

Mortality and incidence of second cancers following treatment for testicular cancer.

Clin Genitourin Cancer, 2019 Mar 13

Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.

Medical Oncology

Genitourinary Cancers

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology